ORLANDO, Fla., Dec. 28 /PRNewswire-FirstCall/ -- GeneLink BioSciences, Inc., a leading consumer genomics and biotechnology company (www.genelinkbio.com), is pleased to announce the appointment of David L. Macdonald as its interim Chief Executive Officer, effective December 28, 2009.
Prior to joining GeneLink, Mr. Macdonald served as the President and Chief Operating Officer at Nichols Institute Diagnostics (NID). Upon acquisition of NID by Corning Life Sciences and the eventual spinout of Quest Diagnostics, Mr. Macdonald became a Vice President at Quest where, along with having responsibility for NID, he was a senior team member of Quest - a $5 billion laboratory services business with 30,000 employees. He also served as CEO and Director at AltheaDx, CEO, President and Director at Nanomix, Senior Vice President of Global Operations and Business Development at Nanogen, and as CEO, President and a member of the Board of Directors at Progeny Systems.
GeneWize has successfully introduced scientific advancements in genetics to the consumer in the form of its LifeMap Me(TM) custom nutritional and skin care formulas. The company has shipped over 50,000 units and achieved over $14M in commercial revenue since its launch in the third quarter of 2008.
David Macdonald stated, "My goal is to focus our efforts and develop core capabilities that will bring GeneLink and GeneWize to the next level. I am excited to be part of the team."
About GeneLink BioSciences, Inc:
About GeneWize Life Sciences, Inc:
Every LifeMap Me(TM) custom nutritional formula and LifeMap Me(TM) custom skin care formula is "made exclusively" for each customer. This is a revolutionary new scientific approach to delivering products that truly address individual needs. GeneWize is committed to innovating and manufacturing the highest quality, scientifically proven health, beauty and wellness products. For more information on GeneWize, please visit: www.genewize.com.
GeneLink BioSciences, Inc.